Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teikoku Seiyaku Co. Ltd.

www.teikoku.co.jp

Latest From Teikoku Seiyaku Co. Ltd.

Teva Strikes Two Settlements Over ‘Pay-For-Delay’ Agreements

A California Court has secured four major settlements worth $70m with pharmaceutical companies over allegations of entering into collusive pay-for-delay agreements, including two with Teva.

Deals Generic Drugs

Market Intel: Pain Is Biggest Market For Transdermal Drug Delivery But Not A Patch Over Neuro For Growth

The growing aging population and rising obesity rates are paving the way for patch-based drug delivery systems to treat such common age-related diseases as Alzheimer's and Parkinson's, hormonal deficiencies, heart disease, as well as for managing acute and chronic pain patients. According to a new report by Meddevicetracker, the global market for transdermal patch products will reach $8.1bn by 2021, a CAGR of 2.9% from 2016. In this feature, we'll take a closer look at the overall market and the key players in the individual segments in this overall market. We'll take a deep dive into the neurological disorders segment, which is expected to see the biggest growth in the overall segment. We'll also feature physician specialty surveys outlining the pros and cons of using patch-based systems.

Combination Products Market Intelligence

FTC Focus On Pay-For-Delay Deals Continues; Endo Agrees To 10-Year Abstention

In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.

BioPharmaceutical Policy & Regulation

FTC v. Endo: Does No-Authorized Generic Agreement Meet Supreme Court Pay-For-Delay Test?

FTC alleges Endo's Opana ER patent settlement with Impax gave it time to introduce a reformulated product; agency also challenges side deal on Parkinson's disease drug and Endo's Lidoderm settlement with Watson.

BioPharmaceutical Legal Issues
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
    • OTC, Consumer
  • Therapeutic Areas
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Teikoku Seiyaku Co. Ltd.
  • Senior Management
  • Misako Fujioka, Pres. & CEO
    Shinji Sano, EVP, COO
  • Contact Info
  • Teikoku Seiyaku Co. Ltd.
    Phone: (81) 879 25 2221
    567 Sanbonmatsu, Higashikagawa
    Kagawa, 769-2695
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register